Eosinophilic bioactivities in severe asthma

Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokin...

Full description

Bibliographic Details
Main Authors:	Carr, Tara F., Berdnikovs, Sergejs, Simon, Hans-Uwe, Bochner, Bruce S., Rosenwasser, Lanny J.
Format:	Online
Language:	English
Published:	BioMed Central 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924237/

id	pubmed-4924237
recordtype	oai_dc
spelling	pubmed-49242372016-07-06 Eosinophilic bioactivities in severe asthma Carr, Tara F. Berdnikovs, Sergejs Simon, Hans-Uwe Bochner, Bruce S. Rosenwasser, Lanny J. Review Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics. BioMed Central 2016-06-27 /pmc/articles/PMC4924237/ /pubmed/27386041 http://dx.doi.org/10.1186/s40413-016-0112-5 Text en © Carr et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Carr, Tara F. Berdnikovs, Sergejs Simon, Hans-Uwe Bochner, Bruce S. Rosenwasser, Lanny J.
spellingShingle	Carr, Tara F. Berdnikovs, Sergejs Simon, Hans-Uwe Bochner, Bruce S. Rosenwasser, Lanny J. Eosinophilic bioactivities in severe asthma
author_facet	Carr, Tara F. Berdnikovs, Sergejs Simon, Hans-Uwe Bochner, Bruce S. Rosenwasser, Lanny J.
author_sort	Carr, Tara F.
title	Eosinophilic bioactivities in severe asthma
title_short	Eosinophilic bioactivities in severe asthma
title_full	Eosinophilic bioactivities in severe asthma
title_fullStr	Eosinophilic bioactivities in severe asthma
title_full_unstemmed	Eosinophilic bioactivities in severe asthma
title_sort	eosinophilic bioactivities in severe asthma
description	Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors. Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to refine these strategies and choose likely responders to biotherapeutics.
publisher	BioMed Central
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924237/
_version_	1613600686302298112

Eosinophilic bioactivities in severe asthma

Similar Items